A description of the invention will be available after the patent application is published. Nencki Institute is the sole applicant. For more information contact Technology Transfer Office.
The subject of the patent application are compounds that inhibit transcription factors from the Grainyhead-like (GRHL) family, especially GRHL2, as well as the use of these compounds in the treatment of diseases dependent on the functioning of this protein, in particular in the treatment of cancer. Nencki Institute is the co-applicant with University of Warsaw and National Medicines Institutes. University of Warsaw is the leader in patent protection and commercialization-related activities. For more information contact Technology Transfer Office.
The subject of the patent application is a nitroxyl derivative of polyphenol with the formula: Q-(L-A)n, where Q denotes a group derived from polyphenol; L denotes an ester linking group containing 1 to 3 carbon atoms; A denotes a 5- or 6-membered heterocyclic group containing one nitrogen atom in the form of a nitroxyl radical (NO•), in which both carbon atoms adjacent to the nitroxyl radical are independently substituted by one or two C1-C3 alkyl groups; and n denotes an integer from 1 to 5. The subject of the application also includes methods for obtaining the above-mentioned derivative and its use as an antioxidant, especially an anti-aging agent. Nencki Institute is the co-applicant with University of Warsaw. University of Warsaw is the leader in patent protection and commercialization-related activities. For more information contact Technology Transfer Office.
A description of the invention will be available after the patent application is published. Nencki Institute is the sole applicant. For more information contact Technology Transfer Office.
Isolated peptides, compositions and methods of use for treating tumors infiltrated with macrophages, such as glioblastoma. For more information contact Technology Transfer Office.
A panel of blood RNA markers for the prediction of epilepsy, in particular drug resistant epilepsy, in girls aged up to 24 months with tuberous sclerosis. Nencki Institute is the co-applicant with Medical University of Warsaw, International Institute of Molecular and Cell Biology in Warsaw, and Children’s Memorial Health Institute in Warsaw. Medical University of Warsaw is the leader in patent protection and commercialization-related activities. For more…
A panel of blood RNA markers for the prediction of the occurrence of epilepsy recurrence following drug withdrawal in patients with tuberous sclerosis. Nencki Institute is the co-applicant with Medical University of Warsaw, International Institute of Molecular and Cell Biology in Warsaw, and Children’s Memorial Health Institute in Warsaw. Medical University of Warsaw is the leader in patent protection and commercialization-related activities. For more…
The invention relates to a PKD protein kinase inhibitor for use in preventing or treating obesity in a subject, including preferably also related conditions such as diabetes, wherein the PKD protein kinase inhibitor is administered orally, wherein the PKD protein kinase inhibitor is targeted to act locally in the digestive system, especially in the small intestine. The invention also relates to a pharmaceutical composition comprising a PKD protein kinase inhibitor for use according to the invention. The Nencki Institute is a co-applicant of the patent with University of Würzburg.
The subject of the invention is the BK124.1 compound of Formula I, for use in the treatment of cancer, wherein the cancer is leukemia or another cancer characterized by a clonal increase in the number of white blood cells, wherein the cancer shows resistance to previous treatments, in particular multidrug resistance. The Nencki Institute is a co-applicant of the patent with Centre of Molecular and Macromolecular Studies PAS and Medical Univeristy of Warsaw